Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 300

1.

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.

Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, Li Y, Chen H, Yang H, Hsu PH, Van Allen EM, Freeman GJ, De Carvalho DD, He HH, Sharpe AH, Shi Y.

Cell. 2018 Jun 18. pii: S0092-8674(18)30715-3. doi: 10.1016/j.cell.2018.05.052. [Epub ahead of print]

PMID:
29937226
2.

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.

Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ.

Oncoimmunology. 2018 Feb 1;7(5):e1423172. doi: 10.1080/2162402X.2017.1423172. eCollection 2018.

PMID:
29721378
3.

Role of Selenof as a Gatekeeper of Secreted Disulfide-Rich Glycoproteins.

Yim SH, Everley RA, Schildberg FA, Lee SG, Orsi A, Barbati ZR, Karatepe K, Fomenko DE, Tsuji PA, Luo HR, Gygi SP, Sitia R, Sharpe AH, Hatfield DL, Gladyshev VN.

Cell Rep. 2018 May 1;23(5):1387-1398. doi: 10.1016/j.celrep.2018.04.009.

4.

TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.

Liu HJ, Lizotte PH, Du H, Speranza MC, Lam HC, Vaughan S, Alesi N, Wong KK, Freeman GJ, Sharpe AH, Henske EP.

JCI Insight. 2018 Apr 19;3(8). pii: 98674. doi: 10.1172/jci.insight.98674. [Epub ahead of print]

5.

Role of PD-1 during effector CD8 T cell differentiation.

Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, Ahmed R.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754. doi: 10.1073/pnas.1718217115. Epub 2018 Apr 13.

PMID:
29654146
6.

Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function.

Sage PT, Schildberg FA, Sobel RA, Kuchroo VK, Freeman GJ, Sharpe AH.

J Immunol. 2018 Apr 15;200(8):2592-2602. doi: 10.4049/jimmunol.1701231. Epub 2018 Mar 12.

PMID:
29531164
7.

Correction: B Cells Drive Autoimmunity in Mice with CD28-Deficient Regulatory T Cells.

Zhang R, Sage PT, Finn K, Huynh A, Blazar BR, Marangoni F, Mempel TR, Sharpe AH, Turka LA.

J Immunol. 2018 Apr 1;200(7):2505-2506. doi: 10.4049/jimmunol.1800150. Epub 2018 Feb 23. No abstract available.

PMID:
29475985
8.

Inhibitors of the PD-1 Pathway in Tumor Therapy.

LaFleur MW, Muroyama Y, Drake CG, Sharpe AH.

J Immunol. 2018 Jan 15;200(2):375-383. doi: 10.4049/jimmunol.1701044.

9.

PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.

Juchem KW, Sacirbegovic F, Zhang C, Sharpe AH, Russell K, McNiff JM, Demetris AJ, Shlomchik MJ, Shlomchik WD.

J Immunol. 2018 Jan 15;200(2):834-846. doi: 10.4049/jimmunol.1701076. Epub 2017 Dec 6.

PMID:
29212909
10.

B Cells Drive Autoimmunity in Mice with CD28-Deficient Regulatory T Cells.

Zhang R, Sage PT, Finn K, Huynh A, Blazar BR, Marangoni F, Mempel TR, Sharpe AH, Turka LA.

J Immunol. 2017 Dec 15;199(12):3972-3980. doi: 10.4049/jimmunol.1700409. Epub 2017 Nov 1. Erratum in: J Immunol. 2018 Feb 23;:.

PMID:
29093061
11.

The diverse functions of the PD1 inhibitory pathway.

Sharpe AH, Pauken KE.

Nat Rev Immunol. 2018 Mar;18(3):153-167. doi: 10.1038/nri.2017.108. Epub 2017 Nov 13. Review.

PMID:
28990585
12.

Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state.

Afik S, Yates KB, Bi K, Darko S, Godec J, Gerdemann U, Swadling L, Douek DC, Klenerman P, Barnes EJ, Sharpe AH, Haining WN, Yosef N.

Nucleic Acids Res. 2017 Sep 19;45(16):e148. doi: 10.1093/nar/gkx615.

13.

Erratum: The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection.

Moffett HF, Cartwright ANR, Kim HJ, Godec J, Pyrdol J, Äijö T, Martinez GJ, Rao A, Lu J, Golub TR, Cantor H, Sharpe AH, Novina CD, Wucherpfennig KW.

Nat Immunol. 2017 Sep 19;18(10):1173. doi: 10.1038/ni1017-1173d. No abstract available.

PMID:
28926530
14.

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.

Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW.

J Immunother Cancer. 2017 Sep 19;5(1):77. doi: 10.1186/s40425-017-0278-6.

15.

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, Lo J, Fisher DE, Miao D, Van Allen E, Root DE, Sharpe AH, Doench JG, Haining WN.

Nature. 2017 Jul 27;547(7664):413-418. doi: 10.1038/nature23270. Epub 2017 Jul 19.

16.

The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection.

Moffett HF, Cartwright ANR, Kim HJ, Godec J, Pyrdol J, Äijö T, Martinez GJ, Rao A, Lu J, Golub TR, Cantor H, Sharpe AH, Novina CD, Wucherpfennig KW.

Nat Immunol. 2017 Jul;18(7):791-799. doi: 10.1038/ni.3755. Epub 2017 May 22. Erratum in: Nat Immunol. 2017 Sep 19;18(10 ):1173.

17.

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.

Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH.

J Exp Med. 2017 Apr 3;214(4):895-904. doi: 10.1084/jem.20160801. Epub 2017 Mar 16.

18.

Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.

Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, Sica GL, Sharpe AH, Freeman GJ, Blazar BR, Turka LA, Owonikoko TK, Pillai RN, Ramalingam SS, Araki K, Ahmed R.

Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.

19.

Introduction to checkpoint inhibitors and cancer immunotherapy.

Sharpe AH.

Immunol Rev. 2017 Mar;276(1):5-8. doi: 10.1111/imr.12531. No abstract available.

20.

Suppression by TFR cells leads to durable and selective inhibition of B cell effector function.

Sage PT, Ron-Harel N, Juneja VR, Sen DR, Maleri S, Sungnak W, Kuchroo VK, Haining WN, Chevrier N, Haigis M, Sharpe AH.

Nat Immunol. 2016 Dec;17(12):1436-1446. doi: 10.1038/ni.3578. Epub 2016 Oct 3.

21.

Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand interaction.

Rigas D, Lewis G, Aron JL, Wang B, Banie H, Sankaranarayanan I, Galle-Treger L, Maazi H, Lo R, Freeman GJ, Sharpe AH, Soroosh P, Akbari O.

J Allergy Clin Immunol. 2017 May;139(5):1468-1477.e2. doi: 10.1016/j.jaci.2016.08.034. Epub 2016 Oct 4.

22.

Anti-CD48 Monoclonal Antibody Attenuates Experimental Autoimmune Encephalomyelitis by Limiting the Number of Pathogenic CD4+ T Cells.

McArdel SL, Brown DR, Sobel RA, Sharpe AH.

J Immunol. 2016 Oct 15;197(8):3038-3048. Epub 2016 Aug 31.

23.

Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity.

Karunarathne DS, Horne-Debets JM, Huang JX, Faleiro R, Leow CY, Amante F, Watkins TS, Miles JJ, Dwyer PJ, Stacey KJ, Yarski M, Poh CM, Lee JS, Cooper MA, Rénia L, Richard D, McCarthy JS, Sharpe AH, Wykes MN.

Immunity. 2016 Aug 16;45(2):333-45. doi: 10.1016/j.immuni.2016.07.017.

24.

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.

Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, Sharpe AH, Freeman GJ, Germain RN, Nakaya HI, Xue HH, Ahmed R.

Nature. 2016 Sep 15;537(7620):417-421. doi: 10.1038/nature19330. Epub 2016 Aug 2.

25.

Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck recruitment and signaling.

Dobbins J, Gagnon E, Godec J, Pyrdol J, Vignali DA, Sharpe AH, Wucherpfennig KW.

Sci Signal. 2016 Jul 26;9(438):ra75. doi: 10.1126/scisignal.aaf0626.

26.

Mitochondrial Biogenesis and Proteome Remodeling Promote One-Carbon Metabolism for T Cell Activation.

Ron-Harel N, Santos D, Ghergurovich JM, Sage PT, Reddy A, Lovitch SB, Dephoure N, Satterstrom FK, Sheffer M, Spinelli JB, Gygi S, Rabinowitz JD, Sharpe AH, Haigis MC.

Cell Metab. 2016 Jul 12;24(1):104-17. doi: 10.1016/j.cmet.2016.06.007.

27.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

28.

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA.

Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.

29.

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.

Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, Vincent BG, Tkachev V, Pawlicki JM, Furlan SN, Kean LS, Aoyama K, Taylor PA, Panoskaltsis-Mortari A, Foncea R, Ranganathan P, Devine SM, Burrill JS, Guo L, Sacristan C, Snyder NW, Blair IA, Milone MC, Dustin ML, Riley JL, Bernlohr DA, Murphy WJ, Fife BT, Munn DH, Miller JS, Serody JS, Freeman GJ, Sharpe AH, Turka LA, Blazar BR.

J Clin Invest. 2016 Jul 1;126(7):2642-60. doi: 10.1172/JCI85796. Epub 2016 Jun 13.

30.

CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease.

Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, Barber DL.

PLoS Pathog. 2016 May 31;12(5):e1005667. doi: 10.1371/journal.ppat.1005667. eCollection 2016 May.

31.

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Schildberg FA, Klein SR, Freeman GJ, Sharpe AH.

Immunity. 2016 May 17;44(5):955-72. doi: 10.1016/j.immuni.2016.05.002. Review.

32.

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA.

Oncoimmunology. 2016 Feb 2;5(3):e1136044. eCollection 2016 Mar.

33.

T follicular regulatory cells.

Sage PT, Sharpe AH.

Immunol Rev. 2016 May;271(1):246-59. doi: 10.1111/imr.12411. Review.

PMID:
27088919
34.

Coinhibitory Pathways in Immunotherapy for Cancer.

Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH.

Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25. Review.

PMID:
26927206
35.

Roles of CD48 in regulating immunity and tolerance.

McArdel SL, Terhorst C, Sharpe AH.

Clin Immunol. 2016 Mar;164:10-20. doi: 10.1016/j.clim.2016.01.008. Epub 2016 Jan 18. Review.

36.

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.

Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, Mautino MR, Celis E, Sharpe AH, Francisco LM, Powell JD, Yagita H, Mellor AL, Blazar BR, Munn DH.

Sci Adv. 2015 Nov 6;1(10):e1500845. doi: 10.1126/sciadv.1500845. eCollection 2015 Nov.

37.

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.

Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ.

Cancer Immunol Res. 2016 Feb;4(2):124-35. doi: 10.1158/2326-6066.CIR-15-0151. Epub 2015 Nov 6.

38.

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.

Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, Hodi FS, Sharpe AH, Signoretti S, Rodig SJ, Freeman GJ.

Cancer Immunol Res. 2015 Dec;3(12):1308-15. doi: 10.1158/2326-6066.CIR-15-0116. Epub 2015 Nov 6.

39.

CD39 Expression Identifies Terminally Exhausted CD8+ T Cells.

Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, Cosgrove C, Ledderose C, Junger WG, Robson SC, Wherry EJ, Alter G, Goulder PJ, Klenerman P, Sharpe AH, Lauer GM, Haining WN.

PLoS Pathog. 2015 Oct 20;11(10):e1005177. doi: 10.1371/journal.ppat.1005177. eCollection 2015 Oct.

40.

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.

Paterson AM, Lovitch SB, Sage PT, Juneja VR, Lee Y, Trombley JD, Arancibia-Cárcamo CV, Sobel RA, Rudensky AY, Kuchroo VK, Freeman GJ, Sharpe AH.

J Exp Med. 2015 Sep 21;212(10):1603-21. doi: 10.1084/jem.20141030. Epub 2015 Sep 14.

41.

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.

Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC Jr, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T.

Cell. 2015 Sep 10;162(6):1242-56. doi: 10.1016/j.cell.2015.08.052.

42.

ABCB5 Identifies Immunoregulatory Dermal Cells.

Schatton T, Yang J, Kleffel S, Uehara M, Barthel SR, Schlapbach C, Zhan Q, Dudeney S, Mueller H, Lee N, de Vries JC, Meier B, Vander Beken S, Kluth MA, Ganss C, Sharpe AH, Waaga-Gasser AM, Sayegh MH, Abdi R, Scharffetter-Kochanek K, Murphy GF, Kupper TS, Frank NY, Frank MH.

Cell Rep. 2015 Sep 8;12(10):1564-74. doi: 10.1016/j.celrep.2015.08.010. Epub 2015 Aug 28.

43.

Defective TFH Cell Function and Increased TFR Cells Contribute to Defective Antibody Production in Aging.

Sage PT, Tan CL, Freeman GJ, Haigis M, Sharpe AH.

Cell Rep. 2015 Jul 14;12(2):163-71. doi: 10.1016/j.celrep.2015.06.015. Epub 2015 Jul 2.

44.

T follicular regulatory cells in the regulation of B cell responses.

Sage PT, Sharpe AH.

Trends Immunol. 2015 Jul;36(7):410-8. doi: 10.1016/j.it.2015.05.005. Epub 2015 Jun 17. Review.

45.

The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells.

Khor B, Gagnon JD, Goel G, Roche MI, Conway KL, Tran K, Aldrich LN, Sundberg TB, Paterson AM, Mordecai S, Dombkowski D, Schirmer M, Tan PH, Bhan AK, Roychoudhuri R, Restifo NP, O'Shea JJ, Medoff BD, Shamji AF, Schreiber SL, Sharpe AH, Shaw SY, Xavier RJ.

Elife. 2015 May 22;4. doi: 10.7554/eLife.05920.

46.

In vitro assay to sensitively measure T(FR) suppressive capacity and T(FH) stimulation of B cell responses.

Sage PT, Sharpe AH.

Methods Mol Biol. 2015;1291:151-60. doi: 10.1007/978-1-4939-2498-1_13.

PMID:
25836309
47.

Helicobacter pylori cag pathogenicity island's role in B7-H1 induction and immune evasion.

Lina TT, Alzahrani S, House J, Yamaoka Y, Sharpe AH, Rampy BA, Pinchuk IV, Reyes VE.

PLoS One. 2015 Mar 25;10(3):e0121841. doi: 10.1371/journal.pone.0121841. eCollection 2015.

48.

ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity.

Maazi H, Patel N, Sankaranarayanan I, Suzuki Y, Rigas D, Soroosh P, Freeman GJ, Sharpe AH, Akbari O.

Immunity. 2015 Mar 17;42(3):538-51. doi: 10.1016/j.immuni.2015.02.007. Epub 2015 Mar 10.

49.

Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability.

Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, Townamchai N, Gerriets VA, Rathmell JC, Sharpe AH, Bluestone JA, Turka LA.

Nat Immunol. 2015 Feb;16(2):188-96. doi: 10.1038/ni.3077. Epub 2015 Jan 5.

50.

Inducible RNAi in vivo reveals that the transcription factor BATF is required to initiate but not maintain CD8+ T-cell effector differentiation.

Godec J, Cowley GS, Barnitz RA, Alkan O, Root DE, Sharpe AH, Haining WN.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):512-7. doi: 10.1073/pnas.1413291112. Epub 2014 Dec 29. Erratum in: Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):E4968. Alkan, Ozan [added].

Supplemental Content

Loading ...
Support Center